Korea Institute of Science and Technology

University of Ulsan Foundation for Industry Cooperation

The Asan Foundation

Mihue Jang

Jong Hwan Kim

Ick Chan Kwon

Hyung Jun Ahn

Eunsung Jun

Anna Ju

Provided are a genetically modified immunocyte expressing a chimeric antigen receptor (CAR) comprising an antigen binding domain specifically binding to cancer cells and/or expressing TRAIL, a composition for preventing or treating cancer, the composition comprising the immunocytes, a cell therapeutic agent, a method of providing information for cancer diagnosis, and a method of preparing the genetically modified immunocyte.

Immunocytes expressing a chimeric antigen receptor binding to cancer cells and TNF-related apoptosis-inducing ligand (trail)

A RNA/DNA nanoparticle for delivering siRNA where a RNA transcript including at least one hairpin structure hybridizes DNA-cholesterol conjugate and folate-DNA conjugate including a complementary sequence to the RNA transcript, and a composition including the RNA/DNA nanoparticle is provided. More specifically, because various siRNA used for different applications can be contained in the RNA/DNA nanoparticle for delivering siRNA at a high loading efficiency, and has stability to the outer attacks such as nuclease degradation. The RNA/DNA nanoparticle siRNA can be prepared by self-assembly without using polycationic agent which is harmful agent for body. The folate targeting to various cancer cells can accumulate the nanoparticle selectively on target cancer cell after intravenous injection, and make excellent gene-silencing effect inside the cancer tissue, thereby being used as a good agent for treating cancers.

RNA/DNA nanoparticle for siRNA target-specific delivery and vehicle including the same

Growing community of inventors

Seoul, South Korea

Mihue Jang